10% tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: A follow-up validation study

Oncologist

Volumn 19, Issue 5, 2014, Pages 507-514

  Krajewski, Katherine M ^a,b   Franchetti, Yoko ^c   Nishino, Mizuki ^a,b   Fay, André P ^a   Ramaiya, Nikhil ^a,b   Van Den Abbeele, Annick D ^a,b   Choueiri, Toni K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Choi; RECIST 1.0; Renal cell carcinoma; Tumor shrinkage; VEGF targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; FORETINIB; PAZOPANIB; SORAFENIB; SUNITINIB; TIVOZANIB; VATALANIB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR DIAMETER; TUMOR VOLUME; VALIDATION STUDY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PROCEDURES; RADIOGRAPHY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900027967     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0391     Document Type: Article

References (27)

1. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model: A population based study. Lancet Oncol 2013;14:141-148.
2. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
3. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
5. Escudier B, Eisen T, Stadler WM et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
6. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883-1887.
7. Thiam R, Fournier LS, Trinquart L et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010;21:936-941.
8. Krajewski KM, Guo M, Van den Abbeele AD et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011;59:856-862.
9. van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803-809.
10. Smith AD, Lieber ML, Shah SN.Assessingtumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194: 157-165.
11. Smith AD, Shah SN, Rini BI et al. Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194: 1470-1478.
12. Schmidt N, Hess V, Zumbrunn T et al. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2013;23:632-639.
13. Hittinger M, Staehler M, Schramm N et al. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol 2012;30:695-703.
14. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.
15. George D, Michaelson D, Oh WK et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: abstract 1548.
16. Stadler WM, Figlin RA, McDermott DF et al; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-1280.
17. Motzer RJ, Hutson TE, Reeves J et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. Paper presented at: 2012 ESMO Congress; October 1, 2012, Abstract LBA8; Vienna, Austria.
18. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/ VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-186.
19. Hutson TE, Rathmell K, Hudes GR et al. A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 2012;30(suppl): abstract TPS4686.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
21. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
22. Nishino M, Jagannathan JP, Ramaiya NH et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010;195:281-289.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
24. Smith AD, Shah SN, Rini BI et al. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminaryanalysis. Urol Oncol 2013;31: 1283-1291.
25. Coriat R, Ropert S, Mir O et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011;29:1090-1093.
26. Sonpavde G, Bellmunt J, Schutz F et al. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep 2012;14:295-306.
27. Krajewski KM, Nishino M, Franchetti Y et al. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria. Cancer 2014;120:711-721.